Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.
Gordon
M F
MF
Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York.
Diaz-Olivo
R
R
Hunt
A L
AL
Fahn
S
S
D000081:Acetamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001479:Basal Ganglia / Q000187:drug effects / Q000503:physiopathology; D001812:Blood-Brain Barrier / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005998:Glycine / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D009435:Synaptic Transmission / Q000187:drug effects; D014743:Videotape Recording
D000081:Acetamides; C039332:milacemide; D005998:Glycine